<span item_type="fundamental" item_id="6f9f8976729fcf3c82713cd2bb2fe184" counter_id="ST/US/KALV" env="prod"></span><span item_type="announcement" item_id="559463011406647553" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 1.426 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -1.12, missing the estimate of USD -0.955.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -57.94 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li><strong>Product Revenue, Net</strong>: $1.4 million for the three months ended July 31, 2025, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li><strong>Cost of Revenue</strong>: $0.6 million for the three months ended July 31, 2025, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Research and Development Expenses</strong>: $15.2 million for the three months ended July 31, 2025, compared to $26.6 million for the same period in 2024, a decrease of $11.5 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: $44.7 million for the three months ended July 31, 2025, compared to $17.6 million for the same period in 2024, an increase of $27.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Net Loss</strong>: $60.1 million for the three months ended July 31, 2025, compared to $40.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $54.5 million for the three months ended July 31, 2025, compared to - $40.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: $21.3 million for the three months ended July 31, 2025, compared to $37.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $23.2 million for the three months ended July 31, 2025, compared to $3.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>Royalty Obligation</strong>: $132.3 million as of July 31, 2025, with an embedded derivative liability fair value of $9.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Deferred Revenue</strong>: $11.0 million as of July 31, 2025, related to the Kaken Agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>Commercialization of EKTERLY</strong>: The company anticipates continued losses as it commercializes EKTERLY, completes post-approval regulatory obligations, and develops additional product candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li><li><strong>Revenue Generation</strong>: The company expects to generate revenue from EKTERLY and other products, while potentially seeking additional financing through equity offerings, debt financing, corporate partnerships, and product sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li><strong>License Agreement with Kaken</strong>: The company entered into a License, Supply, and Distribution Agreement with Kaken Pharmaceutical Co., Ltd. for exclusive commercialization rights in Japan, with potential regulatory and sales milestone payments totaling approximately $13.0 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul><h4>Priority</h4><ul><li><strong>Financial Stability</strong>: The company currently anticipates having sufficient funding to operate for at least the next twelve months based on its operating plans and existing capital resources.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348911/000119312525200757/kalv-20250731.htm"></span></li></ul>

KalVista Pharma | 10-Q: FY2026 Q1 Revenue: USD 1.426 M